Jerusalem light rail gets NIS 280m. loan

Citypass will receive EU290m. as a short-term loan to be returned over three years.

By DANIEL KENNEMER
January 23, 2006 07:19
1 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Bank Hapoalim and Bank Leumi each agreed to loan NIS 140 million to Citypass, the consortium building and operating the initial Red Line of the Jerusalem light rail, in the first installation of a total funding pact worth about NIS 2 billion, the project's manager said Sunday. Citypass will receive EU290m. as a short-term loan to be returned over three years. An additional EU70m. will be provided for 23 years. Once operational, NIS 1.4b. will be paid to Citypass to cover construction costs for the line, which will be transferred to full state ownership after running for 27 years. Citypass had invested NIS 50m. in planning and arranging permits.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS